FDA grants accelerated approval to Bayer's Hyrnuo for HER2-mutated NSCLC
The FDA accelerated approval makes Hyrnuo an approved first-line targeted therapy option for HER2-mutated non-small cell lung cancer in the US.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.